Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies (Q44468289)

3 December 2017

0 references

Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies (English)

1 reference

3 December 2017

2

R R Recker

0 references

author name string

P D Miller

1

1 reference

3 December 2017

R R Recker

2

1 reference

3 December 2017

S Harris

3

1 reference

3 December 2017

S Silverman

4

1 reference

3 December 2017

D Felsenberg

5

1 reference

3 December 2017

J Reginster

6

1 reference

3 December 2017

B-M Day

7

1 reference

3 December 2017

C Barr

8

1 reference

3 December 2017

D Masanauskaite

9

1 reference

3 December 2017

language of work or name

English

0 references

publication date

18 October 2013

1 reference

Osteoporosis International

3 December 2017

published in

1 reference

3 December 2017

volume

25

1 reference

3 December 2017

issue

1

1 reference

3 December 2017

page(s)

349-357

1 reference

Bisphosphonates in osteoporosis: recent clinical experience

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Hospitalization-related bone loss and the protective effect of risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Osteoporosis therapies: evidence from health-care databases and observational population studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Benefits and risks of bisphosphonate therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Bisphosphonates for osteoporosis--where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Severely suppressed bone turnover and atypical skeletal fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Incidence of atypical nontraumatic diaphyseal fractures of the femur

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Exploring the Relationship Between Surrogates and Clinical Outcomes: Analysis of Individual Patient Data vs. Meta-regression on Group-Level Summary Statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-013-2518-Z

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

21 January 2018

1 reference

12 December 2020

Bone densitometry: the best way to detect osteoporosis and to monitor therapy

1 reference

12 December 2020

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

More on atypical fractures of the femoral diaphysis

1 reference

12 December 2020

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis

1 reference

12 December 2020

Diagnosis and treatment of osteoporosis

1 reference

12 December 2020

Bone strength and surrogate markers: the first, second, and third fiddle

1 reference

12 December 2020

Monitoring osteoporosis therapies

1 reference

12 December 2020

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

12 December 2020

More on atypical fractures of the femoral diaphysis.

1 reference

12 December 2020

10.1007/S00198-013-2518-Z

Identifiers

DOI

1 reference

3 December 2017

1 reference